CGEN

#3075
Compugen Ltd. - Ordinary Shares
2.6 3 USD
-5.40%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
2.63
2.63
1年のレンジ
1.32
3.24
1日の変化
-5.40%
月次変化
+0.38%
6か月変化
+67.52%
1年の変化
+69.68%
以前の終値
2.7 8
Open
2.6 3
安値
2.6 3
High
2.6 3
ボリューム
11
チャート全体を表示 Full chart

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 248.67 M
  • Employee 75
  • Founded 1993
  • CEO Anat Cohen-Dayag
  • Website www.cgen.com
  • Headquarter Israel
  • FIGI UNKNOWN
  • Industry 生物工学
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
4.03
売上高対価格比率
1.97

Compugen Ltd. - Ordinary Shares

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

ニュース